Jennifer Lynne Fox - Dec 9, 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role: EVP, Ext Aff, GC, Corp Sec
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Stock symbol: EBS
Transactions as of: Dec 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/13/2022, 04:18 PM
Previous filing: Nov 15, 2022
Next filing: Feb 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EBS	Common Stock	Award	$0	+14K	+43.6%	$0.00	46.3K	Dec 9, 2022	Direct	F1
transaction	EBS	Common Stock	Award	$0	+42.1K	+91.09%	$0.00	88.4K	Dec 9, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F2	Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the day prior to the second anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Content

Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the day prior to the second anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.